Nephrology

NCI-CCC Tumor Board Question

These are questions being discussed by academics at NCI-Cancer Centers

Questions discussed in this category

How do you approach treatment for patients with proliferative glomerulonephritis with monoclonal IgG deposits (PGNMID) with end-stage renal disease who are considering kidney transplant?

Most patients with PGNMID have no detectable disease in their marrow or blood and urine protein cannot adequately be monitored.

1 Answer available

Is there still a role for plasma exchange/PLEX for confirmed or suspected cast nephropathy in multiple myeloma to rapidly reduce light chain burden?

In addition to reversing hypercalcemia, initiating myeloma therapy, etc.

1 Answer available

Papers discussed in this category

Journal of the American Society of Nephrology : JASN, 2007-03

Efficient removal of immunoglobulin free light chains by hemodialysis for multiple myeloma: in vitro and in vivo studies.

Lancet Haematol, 2019 Mar 11

High cutoff versus high-flux haemodialysis for myeloma cast nephropathy in patients receiving bortezomib-based chemotherapy (EuLITE): a phase 2 randomised controlled trial.

Kidney international, 2018-07

Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft.

BMC nephrology, 2019-02-14

Complete biopsy-proven resolution of deposits in recurrent proliferative glomerulonephritis with monoclonal IgG deposits (PGNMIGD) following rituximab treatment in renal allograft.

Related Topics in Nephrology